Calendario›ARVN›ARV-6723
ARV-6723
A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
Ensayo de ARVINAS, INC. en Tumor solido avanzado.
Más ensayos de: Tumor sólido avanzado.
- Fase
- Fase 1/2
- Estado
- Reclutando pacientes
- Participantes
- 499
- Centros
- 3
- Fin del objetivo primario
- mar 2031
Qué significa cada fase y cada estado.
Estudio de intervención, aleatorizado, abierto. Comenzó en jul 2026.
Qué mide
Parte A1: Numero de toxicidades limitantes de dosis (DLT) de ARV-6723 (21 days from first ARV-6723 administration) (del registro, en inglés)
Qué se prueba
El ensayo examina el fármaco en investigación ARV-6723 en participantes con tumores sólidos avanzados.
Lo que dice el documentoThis is a study to evaluate the safety and potential anti-tumor activity of an investigational drug called ARV-6723, in participants with advanced solid tumors. This is an open-label study which means that participants and study staff will know that all participants will receive ARV-6723.
Traducción automática (claude-sonnet-5), con la cita comprobada contra el documento y revisada por una persona.
Cómo lo describe el promotor
En el documentoEn inglés, del registroThis is a study to evaluate the safety and potential anti-tumor activity of an investigational drug called ARV-6723, in participants with advanced solid tumors. This is an open-label study which means that participants and study staff will know that all participants will receive ARV-6723. The investigational drug ARV-6723 will be given as an oral tablet on its own and also in combination with other drugs. Researchers think that ARV-6723 can help the body's immune system to better recognize, attack, and destroy cancer cells in adults with advanced solid tumors. ARV-6723 is an investigational drug, and this is the first time ARV-6723 will be used in humans. Depending on the treatment assignment, the investigational drug, ARV-6723, will be given as an oral tablet either on its own (monotherapy) or in combination with pembrolizumab, either through a vein (intravenously or IV) or through an injection beneath the skin (subcutaneously or SQ). This study will include multiple parts: In Part A1 (Phase 1a), different small groups of participants will receive lower to higher doses of ARV-6723 as monotherapy or in combination with standard-dose of pembrolizumab. In Part A2 (Phase 1b), two groups of participants with specific tumor indication(s) (TBD) will receive one of two doses selected based on information from Part A1. Details of Part B will be determined based on information generated from Part A.
Más ensayos de ARVN
| Ensayo | Fase | Estado | Lectura de resultados |
|---|---|---|---|
| ARV-806 | Fase 1/2 | En marcha, sin reclutar | nov 2026 (prevista) |
| ARV-393 | Fase 1 | Reclutando pacientes | mar 2028 (prevista) |
| Vepdegestrant · mBC | Fase 1/2 | Completado | sep 2024 (real) |
| ARV-471 | Fase 2 | Completado | jul 2024 (real) |
| TACTIVE-E | Fase 1 | Completado | jul 2024 (real) |
| Bavdegalutamide | Fase 1 | Completado | jul 2024 (real) |
Todos los de ARVN, en su ficha.
Ficha completa en ClinicalTrials.gov (NCT07749586), actualizada en ago 2026.